Latest Perspectives on Alzheimer's Disease Treatment: The Role of Blood-Brain Barrier and Antioxidant-Based Drug Delivery Systems

There has been a growing interest recently in exploring the role of the blood-brain barrier (BBB) in the treatment of Alzheimer's disease (AD), a neurodegenerative disorder characterized by cognitive decline and memory loss that affects millions of people worldwide. Research has shown that the...

Full description

Saved in:

Bibliographic Details
Published in:	Molecules (Basel, Switzerland) Vol. 29; no. 17; p. 4056
Main Authors:	Daraban, Bianca Sânziana, Popa, Andrei Sabin, Stan, Miruna S
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 27-08-2024
Subjects:	Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Alzheimer’s disease Animals antioxidant molecules Antioxidants - administration & dosage Antioxidants - chemistry Antioxidants - pharmacokinetics Antioxidants - pharmacology Antioxidants - therapeutic use blood-brain barrier Blood-Brain Barrier - drug effects Blood-Brain Barrier - metabolism Drug Delivery Systems Humans Nanoparticles - chemistry Neurodegeneration Oxidative Stress - drug effects Pathology Toxicity blood-brain barrier Alzheimer’s disease antioxidant molecules
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	There has been a growing interest recently in exploring the role of the blood-brain barrier (BBB) in the treatment of Alzheimer's disease (AD), a neurodegenerative disorder characterized by cognitive decline and memory loss that affects millions of people worldwide. Research has shown that the BBB plays a crucial role in regulating the entry of therapeutics into the brain. Also, the potential benefits of using antioxidant molecules for drug delivery were highlighted in Alzheimer's treatment to enhance the therapeutic efficacy and reduce oxidative stress in affected patients. Antioxidant-based nanomedicine shows promise for treating AD by effectively crossing the BBB and targeting neuroinflammation, potentially slowing disease progression and improving cognitive function. Therefore, new drug delivery systems are being developed to overcome the BBB and improve the delivery of therapeutics to the brain, ultimately improving treatment outcomes for AD patients. In this context, the present review provides an in-depth analysis of recent advancements in AD treatment strategies, such as silica nanoparticles loaded with curcumin, selenium nanoparticles loaded with resveratrol, and many others, focusing on the critical role of the BBB and the use of antioxidant-based drug delivery systems.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1420-3049 1420-3049
DOI:	10.3390/molecules29174056